On Wednesday, Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), added 13.36% and closed at $5.43 in the last trading session. The last trading range of the stock ranges between $4.66 and $5.84. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and partnershipagreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.
Hilton Worldwide Holdings Inc (NYSE:HLT), jumped 1.33% and closed at $23.61 in the last trading session. The last trading range of the stock ranges between $22.68 and $23.73. The company’s Market capitalization is $23.77 Billion with the total Outstanding Shares of 989.78 million. Hilton Worldwide Holdings Inc. (“Hilton Worldwide” or the “Company”) declared recently that certain selling stockholders associated with The Blackstone Group L.P. have begind a secondary offering of 55,000,000 shares of Hilton Worldwide common stock.
Hilton Worldwide is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of shares in this offering. In addition, none of Hilton Worldwide’s officers or directors are selling any shares of common stock beneficially owned by them in the offering.